This analysis details Sarepta Therapeutics' 2026 net product revenue guidance ranging from $1.2B to $1.4B, primarily split between ELEVIDYS one-time gene therapy and the chronic PMO franchise. The breakdown highlights revenue drivers, patient segments, and the impact of educational initiatives.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Please provide the underlying model split for the $1.2B–$1.4B net product revenue guidance between ELEVIDYS prevalent ambulatory, incident patients, and PMOs.
Financial Analysis: Underlying Model Split of $1.2B–$1.4B Net Product Revenue Guidance for ELEVIDYS and PMOs
Sarepta Therapeutics provided guidance for total net product revenue of $1.2 billion to $1.4 billion in 2026 for their approved therapies, which primarily includes contributions from ELEVIDYS (their one-time gene therapy for Duchenne muscular dystrophy) and their PMO franchise (chronic exon-skipping therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45).
| Revenue Category | Approximate 2026 Guidance | Notes and Context |
|---|---|---|
| PMO Franchise (Chronic Therapies) | Stable, ~$900 million implied | PMO revenues are expected to be stable and easier to forecast due to their chronic nature. 2025 net product revenue from PMOs was $966 million. The 2026 guidance assumes modest declines year-over-year as some patients switch to ELEVIDYS, but ongoing strong compliance (>90%) and clinical value sustain demand123. |
| ELEVIDYS (One-time Gene Therapy) | $300 million to $500 million implied | ELEVIDYS net product revenue is the main source of variability in the $1.2B–$1.4B guidance range. 2025 ELEVIDYS revenue was $899 million, but early 2026 revenue reflects a reset phase due to safety perceptions from events in 2025. The $500 million level reflects a “steady-state mix” of incident (new) patients plus prevalent ambulatory patients. The $300 million floor corresponds to steady state without benefit from new educational/commercial initiatives aimed at accelerating patient starts124. |
Base Scenario ($1.2B total revenue):
Upside Scenario ($1.4B total revenue):
Patient Segments within ELEVIDYS Revenue:
Additional Notes on PMO and ELEVIDYS Interaction:
| Revenue Segment | 2026 Guidance Range | Comments |
|---|---|---|
| ELEVIDYS - Prevalent ambulatory and incident patients | $300 million (floor) to $500 million (upside) | Dependent on timing and success of educational initiatives, with upside coming late 2026 and beyond |
| PMO Franchise | ~$900 million | Stable, minimal yoy decline expected; driven by chronic use and high compliance rates |
| Total Net Product Revenue | $1.2 billion to $1.4 billion | Reflects combined contribution of ELEVIDYS and PMOs |
The underlying model split within the $1.2B–$1.4B net product revenue guidance for 2026 places PMO franchise revenues as stable at around $900 million, while ELEVIDYS revenue accounts for the variable portion between approximately $300 million and $500 million. The variability largely depends on the timing and effectiveness of new educational and commercial initiatives designed to mitigate hesitancy and accelerate treatment starts among prevalent ambulatory and incident Duchenne patients. The onetime nature of ELEVIDYS therapy and the long lead time from enrollment to infusion accentuate the quarter-to-quarter revenue variability. Management views the $1.2B baseline as conservative, with strong confidence in achieving growth toward the $1.4B upside as initiatives take effect in the second half of the year and beyond12456.
1 Earnings Q4 2025 transcript, statements by Doug Ingram and Patrick Moss regarding $1.2B-$1.4B guidance and steady state assumptions.
2 Details on 2025 net product revenues: $966M PMO and $899M ELEVIDYS, with ELEVIDYS revenue floor assumptions.
4 Discussion of enrollment, infusion timing, and impact of delayed infusions on guidance.
7 Strategy to address ambulatory prevalent patient hesitancy based on safety perceptions and educational initiatives.
3 Stability and ongoing value of PMOs with minimal expected impact from competition and approval transitions.
5 Expanded commercial efforts and messaging enhancement to drive ELEVIDYS uptake.
1011 Commentary on dual use of PMOs with ELEVIDYS.
6 Timing of promotional and educational programs and expected delay in revenue impact.
8 Clinical data underscoring benefit-risk profile for ELEVIDYS and impact on patient treatment decisions.
9 Comments on ongoing non-ambulatory patient studies and future opportunities.
13 Quarter-to-quarter revenue variability due to rare disease and one-time therapy factors.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Hecla provides an update on its 2026 silver production guidance and outlines long-term strategies to reach 20 million ounces annually, emphasizing project ramp-ups and potential mine restorations.
Sources used
Research questionWhat revenue contribution came from PMO therapies versus Alevitus in Q1?
Answer outline
📉📊 This report compares Reduction in Force (RIF) actions across Sarepta Therapeutics, Health Catalyst, Target Hospitality, and Strategic Education in Q2 2025, highlighting strategic, financial, and operational impacts. 🤝💼
Deep ResearchSources used
Research questionReduction in force
Answer outline
This report details Sarepta's product revenue distribution in Q1 2026, highlighting the contributions of PMO therapies and Alevitus.
Sources used
Research questionWhat revenue contribution came from PMO therapies versus Alevitus in Q1?
Answer outline
PepsiCo’s Q3 2026 discussion points to broad-based international growth, supported by improving competitiveness and stronger volumes, while leaving the durability of that pace unguaranteed. In North America, management plans to continue targeted pricing, affordability measures, innovation, and marketing investment. The Q4 earnings revision reflected margin pressure from costs, mix, and maintained investment, creating risks to monitor in 2027 without establishing a quantified outlook.
Sources used
Research questionHow sustainable is PepsiCo’s international revenue growth, and what are the forward growth opportunities? In North America, should investors expect changes to pricing or other plans after 2026 volume underperformed expectations, particularly for snacks? What drove the Q4 margin-related earnings revision, and what might it signal about pressures in 2027?
Answer outline
Constellation Brands said it is comfortable with its full-year marketing investment, viewing it as a healthier level after likely underspending in prior years. Management expects marketing to run at about 10% of net sales in the second half, including above 11% in Q3, and said continued sports programming does not mean the overall spending level will rise.
Sources used
Research questionWhat did management say about Ongoing marketing spend levels?
Answer outline
Constellation Brands expects scaled beer brands to remain central to growth, while next-wave brands and newer spaces such as SpikedAde offer additional potential without a quantified contribution forecast. Management described broad FY2027 hedge coverage but did not identify a FY2028 hedge-related cost catch-up; the separate Veracruz depreciation headwind is expected to begin in FY2028.
Sources used
Research questionHow should growth contributions divide among scaled brands, next-wave brands, and newer demand spaces such as SpikedAde? Also, could hedges or contracted operating costs benefit fiscal 2027 and then create a catch-up in fiscal 2028?
Answer outline
McCormick’s Q3 Consumer Americas interventions brought early, uneven progress: shipments and consumption improved sequentially, but lower volume offset pricing and left organic sales flat. For Q4, management’s focus is faster retailer execution, stronger support for weaker cooking-blend and recipe-mix lines, continued targeted demand generation, and mitigation of a packaging constraint that could affect shipments.
Sources used
Research questionHow successful were McCormick's initial Consumer Americas interventions in improving volume trends, and what additional or different actions are needed in Q4 to sustain sequential improvement?
Answer outline
Intuit outlines a dual-path strategy: aggressively scaling assisted tax via TurboTax Live while rebuilding a high-quality DIY funnel to sustain long-term growth.
Sources used
Research questionWhat did management say about Assisted tax growth and DIY quality focus?
Answer outline
Alliant Energy raises its 2026 load-growth outlook to 2–3% driven by faster data-center ramp and stronger core demand, aided by spillover effects from construction activity. O&M margins rise about 1 percentage point, but management attributes the gain largely to timing and weather normalization rather than a durable cost-structure shift; long-term sustainability depends on project execution and ongoing pipeline.
Sources used
Research questionWhat is driving the higher 2026 load growth forecast and the uptick in O&M margins, and are these factors sustainable beyond the near term?
Answer outline
Disney explains that the new U.S. park discounts (including after-2:00 p.m. and Anaheim resident pricing) are targeted promotions designed to drive incremental value and optimize capacity, not signals of weaker demand. Q3 metrics show domestic strength and per-capita growth, supporting a strategy to balance volume with yield as capacity expands.
Sources used
Research questionIn light of domestic strength and international visitation softness, how did management justify the rationale and expected business impact of new U.S. park discount programs such as after-2:00 p.m. pricing and Anaheim resident pricing?
Answer outline
Republic Services provides a concise update on its sustainability portfolio, highlighting ~$40 million in incremental revenue and ~$20 million in incremental EBITDA for the year, strong plastics demand and pricing within Polymer Centers, and a longer-term focus on landfill-diversion and second-life opportunities. RNG-specific metrics aren’t disclosed separately, while the company emphasizes environmentally and economically sustainable returns as the bar for future investments.
Sources used
Research questionActually, that's a good segue into what I wanted to talk about. Maybe taking again a longer-term view. I mean, I think over the last couple of years, you've built a pretty nice sustainability portfolio across RNG, in plastics. And so 2 parts, wanted to get an update on just the returns of those investments, how they're trending as they stand today. But also, I think more importantly, are there any other areas within sustainability or even outside sustainability that might be outside of your core business now that you're kind of exploring, investing in, again, over the medium to long term? So kind of a higher level question there?
Answer outline
Zillow outlines the revenue implications of moving toward more than 75% preferred connections by year-end 2026, including seasonality headwinds and timing effects from Zillow Home Loans, alongside the adoption trajectory for Preview and Showcase on new listings. The discussion highlights timing lags, product-driven revenue dynamics, and an expected reversal in Q1 2027 as transitions lap.
Sources used
Research questionWhat is the revenue impact and seasonality from moving to more than 75% preferred connections by year-end 2026, and what is the adoption trajectory for the 5% of new listings using Zillow's previews and related tools?
Answer outline
Dafinchi